Navigation Links
Parent Project Muscular Dystrophy Endorses Senate Version of Prescription Drug User Fee Act After Patient Voice Strengthened

HACKENSACK, N.J., May 24, 2012 /PRNewswire-USNewswire/ -- As the U.S. Senate continues debate on legislation that seeks to accelerate delivery of safe and effective therapies to patients and to increase the patient voice as part of the therapy review process, Parent Project Muscular Dystrophy (PPMD) is pleased to offer its enthusiastic endorsement of the legislation.


Over the past several months, PPMD – the leading advocacy organization fighting to end Duchenne muscular dystrophy (Duchenne) – has fought to include several key provisions included in the Senate version of the Food and Drug Administration Safety and Innovation Act, commonly referred to as the Prescription Drug User Fee Act or PDUFA. A number of similar provisions are also included in a House bill expected to be voted on by that chamber next week.

"The provisions included in the Senate user fee bill will help expand the patient voice when key decisions are being made, an issue of grave importance to our community and to the larger rare disease community," PPMD President Pat Furlong said.  "The provisions will also provide the FDA with additional tools to more quickly review potential therapies for life-threatening conditions, including Duchenne."

The organization has also supported expanded external expert engagement on key issues such as benefit/risk and trial design, and has urged the FDA to accelerate the timing of various rare disease-focused activities.

"As Congress works to finalize the user fee legislation, PPMD calls upon the U.S. House of Representatives to amend their version of the user fee bill to mirror the patient representative provisions contained in the Senate legislation," Furlong said.

The legislative provisions that strengthen the patient voice throughout the FDA review process parallel the FDA Policy position statement adopted by the PPMD Board of Directors in February, and align with the Congressional request made by the PPMD community during the 2012 Advocacy Conference in Washington, DC.

About Parent Project Muscular Dystrophy

Parent Project Muscular Dystrophy (PPMD) is a national not-for-profit organization founded in 1994 by parents of children with Duchenne and Becker muscular dystrophy.  Our mission is to end Duchenne. We accelerate research, raise our voices in Washington, demand optimal care for all young men, and educate the global community. PPMD is headquartered in Middletown, Ohio with offices in Hackensack, New Jersey.  For more information, visit

SOURCE Parent Project Muscular Dystrophy
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
2. An Open Letter to Parents, Students, School Administrators, & Health Care Officials from Soapopular(R)
3. Survey Shows Parents Best Intentions Out of Step with Expert Recommendations in Protecting Kids from Flu
4. Parents Make Donations to National Autism Association for Cutting-Edge Research
5. Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures
6. Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children
7. The COSHAR Foundation Urges Parents to Ensure Children Are Up-to-Date on Vaccinations
8. Transparent Inc. to Introduce Cell-able, a Unique Human Hepatocyte Array, to U.S. Market at ISSX Meeting
9. National Foundation for Infectious Diseases (NFID) Survey: Parents More Flu Aware and More Likely to Get Kids Vaccinated
10. IQAir HealthPro Plus Selected as a Top 10 Product for Parents
11. deCODE Discovers a Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin
Post Your Comments:
(Date:12/1/2015)... LOS ANGELES , Dec. 1, 2015 ... and development company specializing in oncology, today announced that ... for the company,s pivotal global Phase 3 clinical trial ... sarcoma (STS). Enrollment was originally estimated to be completed in ... trial being conducted under a Special Protocol Assessment from ...
(Date:12/1/2015)... , Dec. 1, 2015   MabVax Therapeutics ... development company, announces it has filed an Investigational New ... Administration (FDA) for the Company,s lead fully human antibody ... FDA acceptance, MabVax plans to initiate the Phase I ... --> --> The planned Phase I ...
(Date:12/1/2015)... CHESTERBROOK, Pa. , Dec. 1, 2015 /PRNewswire/ ... leader, announced the launch of CareFront, a first-of-its-kind ... of patients diagnosed with cancer. Designed to be ... newly diagnosed cancer patients with resources for their ... costs. The program also offers tools to help ...
Breaking Medicine Technology:
(Date:12/1/2015)... , ... December 01, 2015 , ... It’s official: Tattoo ... tattoo — a number even greater among Millennials (a whopping one in three aged ... and more people who are dissatisfied with their ink. In fact, RealSelf , ...
(Date:12/1/2015)... Illinois (PRWEB) , ... December 01, 2015 , ... ... and share medical images have been lifted as IMAGE Information Systems launches MED-TAB™ ... Society of North America Annual Meeting from November 29 to December 4, 2015. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... in the United States. Podiatrists are well aware that psychology-based patient non-compliance (disobedience ... are often catastrophic contributors to diseases of the diabetic foot. The American ...
(Date:12/1/2015)... ... 2015 , ... The importance of volumetric breast density assessment ... numerous abstracts accepted for presentation here, at the 101st Annual Radiology Society of ... use of Volpara Solutions’ quantitative breast imaging software tools for providing breast imaging ...
(Date:12/1/2015)... ... 2015 , ... For many X-rays taken at hospitals, doctors’ ... by the radiologist. The marking utensils are so small, however, they are difficult ... way to alleviate this problem. , He developed the patent-pending MARK N SHOW ...
Breaking Medicine News(10 mins):